In a phase 1 trial followed by translational analyses, patients with acute myeloid leukemia (AML) treated with chimeric antigen receptor (CAR) T cell therapy targeting CD123 experienced high levels of cytokine release syndrome and short-lived clinical responses, probably due to CAR T cell-derived cytokines increasing the viability of AML blasts and antigen persistence.
- Anand S. Bhagwat
- Leonel Torres
- Saar I. Gill
